Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a rising AI stock, but faced pressure after Nvidia divested its stake in the company. Recursion is known for using AI to accelerate drug discovery, recently unveiling a whole-genome map and planning to share business updates on February 25.

Recursion Pharmaceuticals utilizes AI, machine learning, and automation to revolutionize drug discovery, operating the Recursion Operating System. While RXRX has potential, other AI stocks may offer better upside. For those seeking undervalued AI stocks, consider exploring the best short-term AI stock in a free report.

Nvidia recently divested its stake in Recursion Pharmaceuticals, Inc., a company known for its AI-driven drug discovery platform. Despite this setback, Recursion continues to innovate by integrating clinical data and unveiling a whole-genome map of microglial cells to identify new targets in drug development.

Read more at Yahoo Finance: Recursion Pharmaceuticals, Inc. (RXRX) Advances AI Drug Discovery Amid Market Shifts